CytoMed Therapeutics Limited
GDTC · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 5.7% | 90.9% | -51.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93.1% | 93.1% | 174.9% | 89.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -760.9% | -760.9% | -920.4% | -472% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -834.7% | -834.7% | -2,055.1% | -511.6% |
| EPS Diluted | -0.075 | -0.071 | -0.093 | -0.048 |
| % Growth | -5.7% | 24.2% | -93.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |